Clinical Trial Update: EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1) [Phase 1, Phase 2]

View source ↗

Summary

EMITT-1 is a Phase 1/2 clinical trial by Grey Wolf Therapeutics evaluating ERAP-mediated immunopeptidome targeting for advanced solid malignancies; the trial is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Malignancy

Drugs mentioned

• EMITT-1 investigational therapy (ERAP Mediated Immunopeptidome Targeting)

Snippet

Sponsor: Grey Wolf Therapeutics | Conditions: Advanced Solid Malignancy | Phase 1, Phase 2 | Status: RECRUITING